pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
LILLY · news · pharmadog
← back to LILLY
News mentioning LILLY
309
stories
Jun 3, 26
What it will take for more employer GLP-1 coverage
endpoints
Jun 3, 26
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
biopharma dive
Jun 3, 26
STAT+: Legend Biotech emerged as a rare market winner
stat
Jun 3, 26
STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
stat
Jun 3, 26
Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
endpoints
Jun 3, 26
Lilly, Ascidian link up in RNA exon editing pact
biopharma dive
Jun 3, 26
Senior NIH scientist, research fellow charged with bringing deactivated mpox virus into U.S.
stat
Jun 2, 26
Lilly gives hospitals deadline to comply with 340B claims data policy
endpoints
Jun 2, 26
Eli Lilly issues data sharing ultimatum to 340B hospitals
biopharma dive
Jun 2, 26
STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trial
stat
Jun 2, 26
STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more
stat
Jun 2, 26
STAT+: Online care is caught in the crossfire as states crack down on corporate medicine
stat
Jun 1, 26
STAT+: Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts
stat
Jun 1, 26
#ASCO26: Lilly's plenaries; Incyte's frontline data in lymphoma
endpoints
Jun 1, 26
#ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T update
endpoints
Jun 1, 26
STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
stat
Jun 1, 26
STAT+: A turning point for pancreatic cancer patients
stat
Jun 1, 26
CDC says containing the spread of Ebola is top priority
stat
Jun 1, 26
Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfront
endpoints
Jun 1, 26
STAT+: Medicare still won’t say how much covering obesity drugs will cost
stat
May 29, 26
Post-Hoc: Lilly gets more secretive and hides Phase 1 pipeline
endpoints
May 29, 26
STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
stat
May 29, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
May 29, 26
Pfizer, Innovent strike $10B cancer drug deal
biopharma dive
May 29, 26
STAT+: The woman behind the world’s biggest longevity competition
stat
May 28, 26
STAT+: As Ebola outbreak in Central Africa grows, the U.S. turns itself into a fortress
stat
May 28, 26
Lilly obesity meds Foundayo and Zepbound to gain CVS coverage
endpoints
May 28, 26
CVS obesity drug deal puts Lilly on equal footing with Novo
biopharma dive
May 19, 26
STAT+: A new ranking of pharma companies by R&D performance
stat
May 19, 26
STAT+: Eli Lilly tops prominent rankings on pharma R&D performance
stat
← prev
page 8 of 11
next →
